HS-10382+Flumatinib
Phase 1Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10382+Flumatinib is one of 21 small molecule programs targeting Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Myeloid Leukemia
#DrugCompanyPhaseTrials
1Gleevec
NovartisApproved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tasigna
AAzurity Pharmaceuticals
Approved
Venclexta
AbbVieApproved
Bosulif
PPrism Pharmaceuticals
Approved
Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Lynparza
AstraZenecaApproved
Novantrone
EMD SeronoApproved
Cerubidine
HHikma Pharmaceuticals LLC
Approved
Jakafi
IncytePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10382+Flumatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details